June 16, 2025

Can Plasma ctDNA Kinetics Predict Response to Systemic Therapy in Advanced NSCLC?

Based on a systematic review and meta-analysis, plasma circulating tumor DNA (ctDNA) kinetics was found to be predictive of survival outcomes in patients with advanced non–small cell lung cancer (NSCL...

The ASCO Post

June 16, 2025

How Does Medicaid Expansion Affect Access to Care in Patients With NSCLC?

Medicaid expansion was associated with a 2.8% increase in lung cancer surgeries performed and a 2.1% increase in surgeries completed within 90 days of diagnosis at high-volume hospitals.

The ASCO Post

June 16, 2025

Patterns in Adherence to USPSTF Lung Cancer Screening Guidelines

In a study reported as a research letter in JAMA Oncology, Rolle et al found increased overall adherence to the 2021 updated U.S. Preventive Services Task Force (USPSTF) lung cancer screening guidelin...

The ASCO Post

June 16, 2025

Dual Use of Cigarettes and E-Cigarettes on Par With Sole Cigarette Use in Terms of Toxic Exposure

Individuals who reported exclusive use of combustible cigarettes as well as those who reported dual use of both cigarettes and e-cigarettes had similarly high toxicant exposure, according to the resul...

The ASCO Post

June 16, 2025

FDA Approves Therapy for NSCLC With High c-Met Protein Overexpression

The FDA granted accelerated approval to telisotuzumab vedotin-tllv (Emrelis), a c-Met–directed antibody and microtubule inhibitor conjugate, for adults with locally advanced or metastatic, nonsquamous...

The ASCO Post

June 16, 2025

Combination Therapy Could Help Overcome Drug Resistance in Patients With KRAS-Mutated NSCLC

Although the FDA-approved drugs sotorasib and adagrasib have provided hope to some patients with non-small cell lung cancer (NSCLC) by targeting KRAS G12C, the majority of tumors either resist treatme...

The ASCO Post

June 16, 2025

Tobacco Control May Have Prevented Millions of Premature Lung Cancer Deaths in United States

Investigators have examined how tobacco control–driven reductions in smoking prevalence may have helped avert lung cancer–related deaths between 1970 and 2022 in the United States.

The ASCO Post

June 16, 2025

AACR 2025: Oral HER2-Targeted Therapy for Advanced HER2-Mutated Lung Cancer

The novel HER2-targeted tyrosine kinase inhibitor zongertinib elicited durable responses in patients with advanced, previously treated non–small cell lung cancer (NSCLC) that harbored a HER2 mutation,...

The ASCO Post

June 16, 2025

Activity of ROS1 TKI in NSCLC

A pooled analysis of the phase II TRUST-I and TRUST-II trials reported efficacy and safety findings on the use of the oral next-generation ROS1 tyrosine kinase inhibitor (TKI) taletrectinib in ROS1-po...

The ASCO Post